Inhibition of Acyl-CoA Cholesterol Acyltransferase by F12511 (Eflucimibe): Could it be a New Antiatherosclerotic Therapeutic?
Authors: López-Farré, Antonio José1; Sacristán, Daniel1; Zamorano-León, José J.1; San-Martín, Nuria1; Macaya, Carlos1
Source: Cardiovascular Drug Reviews, Volume 26, Number 1, Spring 2008 , pp. 65-74(10)
Publisher: Blackwell Publishing
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Lipid-lowering strategies, particularly with statins, have been extremely useful in the prevention of cardiovascular disease. However, many patients who receive statin monotherapy do not achieve the desired cardiovascular benefits. Accumulation of cholesteryl esters within macrophages constitutes the hallmark of foam cells during atherogenesis. The action of acyl-coenzyme A (CoA): cholesterol acyltransferase (ACAT) leads to formation of cholesterol esters. There are two different ACAT isoforms: ACAT1 and ACAT2. A considerable interest to develop ACAT inhibitors has been emerging. This review has been focused on the current knowledge about a new ACAT inhibitor, F12511 or eflucimibe, and more particularly on its antiatherosclerotic properties.Keywords: ACAT inhibitors; Atherosclerosis; Cholesteryl esters; Eflucimibe
Document Type: Research article
DOI: 10.1111/j.1527-3466.2007.00030.x
Affiliations: 1: Cardiovascular Research Unit, Cardiovascular Institute, Hospital Clínico San Carlos, Madrid, Spain
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content

Click here for Page Help